Prosecution Insights
Last updated: July 17, 2026
Application No. 18/410,227

Mixture of two constitutionally isomeric bisphosphites

Non-Final OA §103
Filed
Jan 11, 2024
Priority
Jan 18, 2023 — EU 23152173.3
Examiner
WITHERSPOON, SIKARL A
Art Unit
Tech Center
Assignee
Evonik Oxeno GmbH & Co. Kg
OA Round
1 (Non-Final)
86%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
66%
With Interview

Examiner Intelligence

Grants 86% — above average
86%
Career Allowance Rate
1422 granted / 1650 resolved
+26.2% vs TC avg
Minimal -20% lift
Without
With
+-20.3%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 8m
Avg Prosecution
29 currently pending
Career history
1673
Total Applications
across all art units

Statute-Specific Performance

§101
2.2%
-37.8% vs TC avg
§103
61.7%
+21.7% vs TC avg
§102
8.1%
-31.9% vs TC avg
§112
4.9%
-35.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1650 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Objections Claim 4 is objected to because of the following informalities: the claim recites “Umicore”, which appears to be a company name, and should be removed. Appropriate correction is required. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1-7 is/are rejected under 35 U.S.C. 103 as being unpatentable over Christiansen et al. (US 9,206,105). The claims are drawn to a mixture comprising compounds (1a) and (1b), and to a hydroformylation process using said mixture, along with a rhodium compound, as catalyst. Christiansen et al. teach a mixture of constitutionally isomeric bisphosphites and a metal, to use as a catalytically active composition in a hydroformylation reaction (abstract). The reference teaches a mixture of compounds (Ia) and (Ib), wherein substituents R1 to R4 are selected from -Me, -tBu, and -OMe. The mixture of bisphosphites may comprise a metal selected from Fe, Ru, Co, Rh, Ni, Pd, and Pt. For example, a rhodium compound, such as Rh(acac)(CO)2 can be used to supply rhodium metal. The catalyst composition taught by Christiansen et al. is used in a process to hydroformylate an olefin, e.g., cis-2-butene, in the presence of toluene as solvent, at a temperature of 120°C, and a pressure of 20 bar (col. 29; claims). The instant claims are rendered obvious by Christiansen et al., since the reference teaches a mixture of bisphosphite ligands, the scope of which encompasses the bisphosphites of instant formula (1a) and (1b), as the substituents on the bisphosphites recited by the reference are such that a person having ordinary skill in the art could readily chose a compound, or compounds that would anticipate the bisphosphite mixture recited in the instant claims. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SIKARL A WITHERSPOON whose telephone number is (571)272-0649. The examiner can normally be reached M-F 9am-9pm IFP. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Goon can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SIKARL A WITHERSPOON/Primary Examiner, Art Unit 1692
Read full office action

Prosecution Timeline

Jan 11, 2024
Application Filed
Jun 16, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12673093
METHOD AND COMPOSITION FOR TREATING ARGINASE 1 DEFICIENCY
3y 0m to grant Granted Jul 07, 2026
Patent 12667833
NANOHYBRID CATALYST FOR HYDROGENATION REACTIONS
2y 9m to grant Granted Jun 30, 2026
Patent 12662443
HIGH PURITY 4-HYDROXYSTYRENE SOLUTION, METHOD OF PRODUCING THE SAME, AND METHOD OF PRODUCING 4-HYDROXYSTYRENE POLYMER
3y 6m to grant Granted Jun 23, 2026
Patent 12655094
CANNABINOID SULFATE ESTERS, THEIR SALTS AND USES THEREOF
3y 10m to grant Granted Jun 16, 2026
Patent 12655085
PREPARATION METHOD AND APPARATUS FOR METHYL METHACRYLATE
2y 9m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
86%
Grant Probability
66%
With Interview (-20.3%)
1y 8m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1650 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month